You are here

Article Text

Article menu
Download PDFPDF
Scientific letters
Effects of perindopril on soluble intercellular adhesion molecule-1 in patients with congestive heart failure
  1. X-M Wang1,
  2. Y Li1,
  3. H-F Li1,
  4. F Liu2,
  5. G-L Jia3
  1. 1Department of Geriatrics, Xijing Hospital, Fourth Military Medical University, Xi'an, China
  2. 2Department of Immunology, College of Basic Medicine, Fourth Military Medical University
  3. 3Department of Cardiology, Xijing Hospital
  1. Correspondence to:
    XiaoMing Wang MD, Department of Geriatrics, Xijing Hospital, Fourth Military Medical University, Xi'an 710032, China;
    xmwang{at}fmmu.edu.cn

https://doi.org/10.1136/heart.88.4.417

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    There is increasing evidence that pro-inflammatory molecules play an important role in the ventricular remodelling of congestive heart failure (CHF).1 Among these molecules, intercellular adhesion molecule-1 (ICAM-1) is a key mediator for the necrosis of cardiac muscle. This study compares, for the first time, the effects of the angiotensin converting enzyme (ACE) inhibitor perindopril and conventional treatment on plasma soluble ICAM-1 (sICAM-1).

    METHODS

    Eighty four patients with CHF presenting to the department of cardiology and department of geriatrics at Xijing Hospital between December 2000 and March 2001 were recruited. Before treatment, the patients were informed about the advantages and disadvantages of perindopril treatment and treated according to their own choice. They were then divided into two treatment groups. The perindopril group comprised 42 patients (32 men, 10 women, mean (SD) age 63.2 (6.2) years, range 37–84 years), with New York Heart Association (NYHA) functional class II (7 patients), III (22 patients), and IV (13 patients) heart failure. The conventional treatment group also comprised 42 patients (25 men, 17 women, mean age 56.5 (7. 6), range 42–79 years) with NYHA functional class II (9 patients), III (19 patients), and IV (14 patients) heart failure. The causes of CHF included rheumatic heart disease (29 patients), coronary heart disease (23 patients), and dilated cardiomyopathy (11 patients). The control group comprised 30 healthy individuals …

    View Full Text